Table 4.

Change of abnormalities based on a 5-year follow-up among the subgroups stratified by ALT and shift work (%)

MetS and its components	e-ALT initially	pRSW exposure	Baseline	P value1	5th yr	P value1	Δ 5th yr vs baseline
Central obesity	No	No	2.8	0.1595	22.2	0.0037	19.4
		Yes	3.2		20.0		16.8
	Yes	No	5.9		33.6		27.7
		Yes	7.0		33.8		26.8
Hyperglycemia	No	No	22.0	0.5658	16.7	< 0.0001	-5.2
		Yes	18.4		13.9		-4.5
	Yes	No	22.7		26.9		4.2
		Yes	18.3		33.8		15.5
Hypertriglyceridemia	No	No	15.1	< 0.0001	26.8	< 0.0001	11.7
		Yes	13.2		25.5		12.3
	Yes	No	34.5		42.0		7.6
		Yes	23.9		45.1		21.1
Elevated blood pressure	No	No	18.3	0.01	48.0	0.1025	29.6
		Yes	20.6		50.0		29.4
	Yes	No	29.4		55.5		26.1
		Yes	31.0		62.0		31.0
Hypo-HDL cholesterol	No	No	18.5	0.0018	6.3	< 0.0001	-12.3
		Yes	17.1		8.1		-9.0
	Yes	No	32.8		17.6		-15.1
		Yes	23.9		23.9		0.0
Development of MetS within 5 yr	No	No			11.1	< 0.0001
		Yes			8.7
	Yes	No			27.7
		Yes			36.6
MetS-component numbers (mode)	No	No	0		1		0
		Yes	0		1		0
	Yes	No	2		1		0
		Yes	1		2		1

¹χ² test was conducted, four abnormalities of subgroups were constructed. Δ: Differences between 2007 and 2002; plus indicates increasing and minus indicates decreasing trend within follow-up.